Menu
Search
|

Menu

Close
X

Neuralstem Inc CUR.OQ (NASDAQ Stock Exchange Capital Market)

0.52 USD
-0.02 (-4.37%)
As of 8:59 PM GMT
chart
Previous Close 0.54
Open 0.56
Volume 25,278
3m Avg Volume 30,979
Today’s High 0.56
Today’s Low 0.51
52 Week High 3.09
52 Week Low 0.48
Shares Outstanding (mil) 12.12
Market Capitalization (mil) 16.36
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.304
FY17
-1.299
FY16
-2.576
FY15
-2.988
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.59
Price to Sales (TTM)
vs sector
1,006.68
5.69
Price to Book (MRQ)
vs sector
2.11
5.11
Price to Cash Flow (TTM)
vs sector
--
23.52
Total Debt to Equity (MRQ)
vs sector
0.00
15.71
LT Debt to Equity (MRQ)
vs sector
0.00
11.53
Return on Investment (TTM)
vs sector
-291.84
15.05
Return on Equity (TTM)
vs sector
-536.03
16.62

EXECUTIVE LEADERSHIP

William Oldaker
Chairman of the Board, Since 2018
Salary: --
Bonus: --
Jim Scully
Interim Chief Financial Officer, Principal Accounting Officer, Since 2018
Salary: --
Bonus: --
David Recker
Chief Medical Officer, Since 2017
Salary: --
Bonus: --
Xi Chen
Director, Since 2017
Salary: --
Bonus: --
Cristina Csimma
Director, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

20271 Goldenrod Ln Ste 2024
GERMANTOWN   MD   20876-4064

Phone: +1301.3664841

Neuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform. The Company's technology allows the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the treatment of central nervous system diseases and conditions. The Company is developing NSI-189 for the treatment of major depressive disorder (MDD) and other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy. The Company's NSI-566 is indicated for amyotrophic lateral sclerosis (ALS), chronic spinal cord injury and motor deficits due to ischemic stroke.

SPONSORED STORIES